Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An Author's Perspective
    • Ask the Experts
    • Bioanalysis articles
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Spotlights
    • Tech Digest
    • T&F journals

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Awareness
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Professional development
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • A loaded tip
  • Unlocking the inner workings of cancer cells
  • Jessica Bridges Weaver named as a 2026 Women in Business award winner

Related tags

antibody Bio-rad biotherapeutics technology
Previous article

Related articles

11 AUG 2015 CLINICAL
Biotransformation and stability of antibody–drug conjugates: payload metabolism and linker cleavage delineation
31 JAN 2013 GENERAL INTEREST
Launch of a US$5 million Parkinson’s Disease Biomarkers Program in the USA
29 APR 2014 GENERAL INTEREST
Raman spectroscopy may be useful in detecting early tooth decay
12 FEB 2026 NEWS
Bruker launches the iNTApharma platform
22 MAR 2011 DATA PROCESSING AND INTERPRETATION
Comparison of an antibody capture and a cell capture ligand-binding assay to quantify a monoclonal therapeutic in serum
21 JUL 2015 DRUG DEVELOPMENT
Starting a CRO on personal credit
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Permissions
  • Whitelist Emails
  • Zone Leaders

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone